Veronique Lecault - 14 Jan 2024 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Operating Officer, Director
Signature
Tryn Stimart, attorney-in-fact
Issuer symbol
ABCL
Transactions as of
14 Jan 2024
Net transactions value
$0
Form type
4
Filing time
16 Jan 2024, 18:23:50 UTC
Previous filing
14 Sep 2023
Next filing
24 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share option (right to buy) Award $0 +770,416 +25% $0.000000 3,913,105 14 Jan 2024 Common Shares 770,416 $5.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.